政策是舵 互联网是桨 医药行业如何“玩转”新零售

2018-08-08 乔丹 健康界

“未来十年二十年,没有电子商务这一说,只有新零售。” 2016年10月马云第一次提出“新零售”概念后,迅速席卷互联网各个角落,各行各业纷纷贴上“新零售+”的标签,医药行业也不例外。和电子商务颠覆商业模式一样,医药电商也被行业视为颠覆力量,撬动了原有医药的流通体系。然而从2016年开始,随着线上流量红利的消退,医药电商发展呈下滑趋势,转换跑道寻找新业务增长点,成为不少电商企业的尝试。“新零售”

“未来十年二十年,没有电子商务这一说,只有新零售。” 2016年10月马云第一次提出“新零售”概念后,迅速席卷互联网各个角落,各行各业纷纷贴上“新零售+”的标签,医药行业也不例外。

和电子商务颠覆商业模式一样,医药电商也被行业视为颠覆力量,撬动了原有医药的流通体系。然而从2016年开始,随着线上流量红利的消退,医药电商发展呈下滑趋势,转换跑道寻找新业务增长点,成为不少电商企业的尝试。“新零售”模式的出现,为医药零售找到了新的出路。

医药新零售“新”在哪?“基于互联网技术,融合医院、药房、诊所、仓储、流通、患者等各个环节,最终赋能终端的服务闭环。”成都新医势科技有限公司董事长、成都泉源堂连锁股份有限公司战略总顾问夏军向健康界表达了自己看法。

政策催生互联网+医药新业态

长期以来,医药零售受制于自身的行业特殊性,普遍呈现出一种“低频刚需”的特点,难以通过营销手段来吸引巨大流量,再加上其受政策管控较严,又对供应链、物流、品控等高度依赖,因而始终难以“减重”成为纯粹的线上业态。也正因为如此,当普通零售经历了从百货商店到连锁商店,再到超级市场的数次变革时,医药零售场景仍长期依存在于医院或线下药房之中。

2018年两会后,国务院正式发布《关于促进“互联网+医疗健康”发展的意见(国办发〔2018〕26号)》,明确允许依托医疗机构发展互联网医院,支持探索医疗机构处方信息与药品零售信息共享,打通在线开方、药师审核、第三方药品配送流程,加快实现医疗保障在线支付和“一站式”结算。

8月3日,国务院办公厅发布《关于改革完善医疗卫生行业综合监管制度的指导意见》。《意见》要求有关部门针对“互联网+医疗健康”等医疗卫生服务新技术、新设备、新业态等,加快标准制修订。

政策春风之下,相关标准的快速落地,无疑给行业以及从业者吃了定心丸。“26号文的发布,意味着医药行业传统的营销模式要升级换代。简单来说,就是零售药店的线上线下融合。”夏军解释道。近年来,探索互联网渠道与传统零售药店的互动融合,以创造药品零售领域的新联动模式,已经成为医药电商与实体药店的共同选择。在医药新零售时代的召唤下,互联网+已成为行业融合发展的新业态。

西安怡康医药连锁有限公司董事长何煜曾公开表示,随着连锁药店新零售的到来,行业将会迎来一个新的机遇——批零一体化。他推测,除了拥抱互联网之外,未来3-5年里,随着医药分开,拥有批零一体化优势资源的企业,会掌握更多机会。

根据波士顿咨询公司发布的研究报告,医院在药品销售中占据高达80%的市场份额,随着“全面取消药品加成”和“限制药占比”等政策的推进,预测到2021年医院的药品销售份额会下降5%~8%,到2026年医院在药品销售中的比例将下降至50%~60%。这便意味着药品销售会逐渐“去医院化”,而线下零售药店与线上医药电商或将迎来一段难得的发展红利期。

如此一来,以往单一的医药零售渠道势必将处于变革的前夜。而在当前“线上线下全面融合”的新零售浪潮下,医药零售同样也需要整合线上与线下,在提高生产运输效率的同时,满足消费者的消费体验与诉求。

打造闭环服务成趋势

基于满足消费者体验与诉求的医药新零售,老百姓大药房连锁股份有限公司董事长谢子龙认为,消费者过去体验诉求小于功能诉求,但现在的转变是体验诉求与功能诉求同样重要。这意味着,连锁药店要从过去单纯的卖药逐步转变成健康服务商。

和他持同样观点的是马应龙大药房连锁有限公司总经理沈熠,他表示,连锁药店新零售强调“新”和融合。过去药店更多只是提供产品服务,未来应该是建立在以消费者为核心,提升药店从产品服务向整个健康服务的转型。

健康服务转型之下,现阶段的零售药店在做多元化的上下游拓展,比如审方、慢病管理、煎药服务、健康管理等。而整个健康服务离不开全流程的闭环联动,在夏军看来,连锁药店的发展迄今为止分三个阶段:

1.0:仅为多个药店的实体连锁;

2.0:实现互联网管理的实体连锁;

3.0:互联网+医疗健康中的医、药、人形成闭环,即可实现实体店服务,又可接互联网医院处方、空中药师服务、配送到家的智慧连锁。

此前,阿里入股漱玉平民和华人健康,则是健康平台之间的价值融合体现,基于平台,利用互联网技术,依托互联网医院(实体医院的互联网化),打造医生、患者、医师、药师、医药人的服务闭环,实现闭环联动,进一步打通线上线下服务。

“其实,互联网和实体医疗是相互成就、取长补短的关系。健康平台做规范,通过闭环联动,促使三甲医院通过医联体,推动下面的小医院或者社区等医疗机构提高技术水平,把看病难问题解决掉。”互联网+新业态惠民益民便民的同时,夏军也强调,医保是闭环联动需要打通的最后一环,“打通医保报销,医药零售行业的变革才是真正意义上的盘活。”

事实上,在医保方面,我国也进行了有益探索。“十三五”期间,医保控费、公立医院药品零差率、药占比限制、医保支付方式改革等新医改政策陆续实施,间接推动了医疗机构处方外配进程;部分区域积极探索医院处方信息、医保结算信息和药店零售信息共享,开展了门诊特病、慢病定点药店医保结算试点,直接推动患者向零售药店流动。

“在此背景下,处方外流预计一年可达3000~5000亿市场规模。”夏军分析称。业内人士也表示,整个大健康行业闭环的医药患检保,最后一个“保”,主要体现在支付环节,如果在商业保险方面的限制比现在的情况有所放开,那释放出来的就会更多,可能又是几万亿的市场需求。

(本文素材来源于21世纪药店、钛媒体等公开报道)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1260367, encodeId=2d95126036ea2, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274202, encodeId=550b12e4202d2, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409648, encodeId=1ea8140964880, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604989, encodeId=bea21604989dc, content=<a href='/topic/show?id=a631353e6e6' target=_blank style='color:#2F92EE;'>#医药行业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35376, encryptionId=a631353e6e6, topicName=医药行业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbd19305036, createdName=fmq_28614559, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337393, encodeId=c6da33e39357, content=不错的文章值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Aug 08 22:50:53 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337381, encodeId=3e7733e38187, content=不错的文章值得拥有,, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Aug 08 22:30:46 CST 2018, time=2018-08-08, status=1, ipAttribution=)]
    2018-08-10 bioon3
  2. [GetPortalCommentsPageByObjectIdResponse(id=1260367, encodeId=2d95126036ea2, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274202, encodeId=550b12e4202d2, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409648, encodeId=1ea8140964880, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604989, encodeId=bea21604989dc, content=<a href='/topic/show?id=a631353e6e6' target=_blank style='color:#2F92EE;'>#医药行业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35376, encryptionId=a631353e6e6, topicName=医药行业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbd19305036, createdName=fmq_28614559, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337393, encodeId=c6da33e39357, content=不错的文章值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Aug 08 22:50:53 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337381, encodeId=3e7733e38187, content=不错的文章值得拥有,, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Aug 08 22:30:46 CST 2018, time=2018-08-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1260367, encodeId=2d95126036ea2, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274202, encodeId=550b12e4202d2, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409648, encodeId=1ea8140964880, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604989, encodeId=bea21604989dc, content=<a href='/topic/show?id=a631353e6e6' target=_blank style='color:#2F92EE;'>#医药行业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35376, encryptionId=a631353e6e6, topicName=医药行业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbd19305036, createdName=fmq_28614559, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337393, encodeId=c6da33e39357, content=不错的文章值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Aug 08 22:50:53 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337381, encodeId=3e7733e38187, content=不错的文章值得拥有,, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Aug 08 22:30:46 CST 2018, time=2018-08-08, status=1, ipAttribution=)]
    2018-08-10 cathymary
  4. [GetPortalCommentsPageByObjectIdResponse(id=1260367, encodeId=2d95126036ea2, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274202, encodeId=550b12e4202d2, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409648, encodeId=1ea8140964880, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604989, encodeId=bea21604989dc, content=<a href='/topic/show?id=a631353e6e6' target=_blank style='color:#2F92EE;'>#医药行业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35376, encryptionId=a631353e6e6, topicName=医药行业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbd19305036, createdName=fmq_28614559, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337393, encodeId=c6da33e39357, content=不错的文章值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Aug 08 22:50:53 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337381, encodeId=3e7733e38187, content=不错的文章值得拥有,, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Aug 08 22:30:46 CST 2018, time=2018-08-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1260367, encodeId=2d95126036ea2, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274202, encodeId=550b12e4202d2, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409648, encodeId=1ea8140964880, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604989, encodeId=bea21604989dc, content=<a href='/topic/show?id=a631353e6e6' target=_blank style='color:#2F92EE;'>#医药行业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35376, encryptionId=a631353e6e6, topicName=医药行业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbd19305036, createdName=fmq_28614559, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337393, encodeId=c6da33e39357, content=不错的文章值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Aug 08 22:50:53 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337381, encodeId=3e7733e38187, content=不错的文章值得拥有,, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Aug 08 22:30:46 CST 2018, time=2018-08-08, status=1, ipAttribution=)]
    2018-08-08 131****2916

    不错的文章值得推荐一下

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1260367, encodeId=2d95126036ea2, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274202, encodeId=550b12e4202d2, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409648, encodeId=1ea8140964880, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604989, encodeId=bea21604989dc, content=<a href='/topic/show?id=a631353e6e6' target=_blank style='color:#2F92EE;'>#医药行业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35376, encryptionId=a631353e6e6, topicName=医药行业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbd19305036, createdName=fmq_28614559, createdTime=Fri Aug 10 12:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337393, encodeId=c6da33e39357, content=不错的文章值得推荐一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Aug 08 22:50:53 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337381, encodeId=3e7733e38187, content=不错的文章值得拥有,, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Aug 08 22:30:46 CST 2018, time=2018-08-08, status=1, ipAttribution=)]
    2018-08-08 1e1b8538m79(暂无匿称)

    不错的文章值得拥有,

    0

相关资讯

涨工资、建机构,护理行业要崛起,卫健委发话了

刚刚,卫健委官网发布促进护理服务业改革发展的指导性文件,护士要涨工资了!

上海再发政策红包 未来有望淡化医院等级

在“上海扩大开放100条”发布14天之后,7月24日,上海《关于推进健康服务业高质量发展加快建设一流医学中心城市的若干意见》面世。上海市副市长翁铁慧介绍了相关情况。据悉,该文件主要聚焦健康医疗、健康服务、健康保险三大领域,由50条构成(简称上海“健康服务业50条”)。“上海扩大开放100条”中与医健产业相关的政策共有8条,上海要将“全面推进药品医疗器械进口枢纽口岸建设”进行到底。仅仅过了14

8月1日后,这项政策正式实施,械企将迎来重大变化!

距CFDA发布新版《医疗器械分类目录》过去了将近1年的缓冲时间,按照之前的公示:新版《医疗器械分类目录》将在2018年8月1日正式实施。

又一重磅政策,要在全医药行业推行

昨日(7月17日),国家药监局就上市许可持有人制度再次发函。回复了上市许可持有人和生产企业各自的权责问题。

医保控费的“梗”怎么解读,谁的权益被破坏?

浙江省某市肿瘤医院医生陈明红,最近发工资时又只拿到了1000元的绩效奖金。半年来,因他所在的呼吸内科医保经费超标,全科的人都被扣钱,奖金只能按保底金额发放。

开放公私合作办医、开放医保数据 这样的政策上海来了五十条

为了将上海建设成为“亚洲医学中心”,上海市将出台一份内容包含医药、养老、精准医疗等多方面多达50项新政的重磅政策,并制定了相关落实的委办局机构。其中关于公私合办非营利性机构、对医保数据的开放等政策尤为值得关注。